An Allele-specific hammerhead ribozyme gene therapy for a porcine model of autosomal dominant retinitis pigmentosa

Molecular Vision

Volumn 7, Issue , 2001, Pages 6-13

  Shaw, Lynn C ^a   Skold, Anna ^a   Wong, Fulton ^b   Petters, Robert ^c   Hauswirth, William ^a   Lewin, Alfred S ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; OLIGONUCLEOTIDE; OPSIN; PROTEIN RET; REAGENT; RHODOPSIN; RIBOZYME; RNA;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOSOMAL DOMINANT DISORDER; DISEASE MODEL; DRUG ACTIVITY; DRUG DETERMINATION; DRUG SPECIFICITY; DRUG TARGETING; GENE MUTATION; GENE SEQUENCE; GENE THERAPY; IN VITRO STUDY; MOLECULAR CLONING; NONHUMAN; PROTEIN METABOLISM; RETINITIS PIGMENTOSA; RNA CLEAVAGE; SEQUENCE HOMOLOGY; SWINE; TRANSGENE;

ALLELES; ANIMALS; ANIMALS, GENETICALLY MODIFIED; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; DNA PRIMERS; GENE THERAPY; GENETIC VECTORS; OPSIN; RETINITIS PIGMENTOSA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, CATALYTIC; RNA, MESSENGER; SWINE; TIME FACTORS; TRANSFECTION;

EID: 0035789119     PISSN: 10900535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Berson EL. Retinitis pigmentosa: unfolding its mystery. Proc Natl Acad Sci U S A 1996; 93:4526-8.
2. Sullivan LS, Daiger SP. Inherited retinal degeneration: exceptional genetic and clinical heterogeneity. Mol Med Today 1996; 2:380-6.
3. Adler R. Mechanisms of photoreceptor death in retinal degenerations. From the cell biology of the 1990s to the ophthalmology of the 21st century? Arch Ophthalmol 1996; 114:79-83.
4. Birch DG. Retinal degeneration in retinitis pigmentosa and neuronal ceroid lipofuscinosis: An overview. Mol Genet Metab 1999; 66:356-66.
5. Phelan JK, Bok D. A brief review of retinitis pigmentosa and the identified retinitis pigmentosa genes. Mol Vis 2000; 6:116-24 .
6. Sandberg MA, Weigel-DiFranco C, Dryja TP, Berson EL. Clinical expression correlates with location of rhodopsin mutation in dominant retinitis pigmentosa. Invest Ophthalmol Vis Sci 1995; 36:1934-42.
7. Deretic D, Schmerl S, Hargrave PA, Arendt A, McDowell JH. Regulation of sorting and post-Golgi trafficking of rhodopsin by its C-terminal sequence QVS(A)PA. Proc Natl Acad Sci U S A 1998; 95:10620-5.
8. Li T, Snyder WK, Olsson JE, Dryja TP. Transgenic mice carrying the dominant rhodopsin mutation P347S: evidence for defective vectorial transport of rhodopsin to the outer segments. Proc Natl Acad Sci U S A 1996; 93:14176-81.
9. Sung CH, Makino C, Baylor D, Nathans J. A rhodopsin gene mutation responsible for autosomal dominant retinitis pigmentosa results in a protein that is defective in localization to the photoreceptor outer segment. J Neurosci 1994; 14:5818-33.
10. Petters RM, Alexander CA, Wells KD, Collins EB, Sommer JR, Blanton MR, Rojas G, Hao Y, Flowers WL, Banin E, Cideciyan AV, Jacobson SG, Wong F. Genetically engineered large animal model for studying cone photoreceptor survival and degeneration in retinitis pigmentosa. Nat Biotechnol 1997; 15:965-70.
11. Tso MO, Li WW, Zhang C, Lam TT, Hao Y, Petters RM, Wong F. A pathologic study of degeneration of the rod and cone populations of the rhodopsin Pro347Leu transgenic pigs. Trans Am Ophthalmol Soc 1997; 95:467-79.
12. Li ZY, Wong F, Chang JH, Possin DE, Hao Y, Petters RM, Milam AH. Rhodopsin transgenic pigs as a model for human retinitis pigmentosa. Invest Ophthalmol Vis Sci 1998; 39:808-19.
13. Peng YW, Hao Y, Petters RM, Wong F. Ectopic synaptogenesis in the mammalian retina caused by rod photoreceptor-specific mutations. Nat Neurosci 2000; 3:1121-7.
14. Shaw LC, Whalen PO, Drenser KA, Yan W, Hauswirth WW, Lewin AS. Ribozymes in treatment of inherited retinal disease. Methods Enzymol 2000; 316:761-76.
15. Feldstein PA, Bruening G. Catalytically active geometry in the reversible circularization of 'mini-monomer' RNAs derived from the complementary strand of tobacco ringspot virus satellite RNA. Nucleic Acids Res 1993; 21:1991-8.
16. Shimayama T, Nishikawa S, Taira K. Generality of the NUX rule: kinetic analysis of the results of systematic mutations in the trinucleotide at the cleavage site of hammerhead ribozymes. Biochemistry 1995; 34:3649-54.
17. Yan W, Lewin A, Hauswirth W. Selective degradation of nonsense beta-phosphodiesterase mRNA in the heterozygous rd mouse. Invest Ophthalmol Vis Sci 1998; 39:2529-36.
18. Hauswirth WW, LaVail MM, Flannery JG, Lewin AS. Ribozyme gene therapy for autosomal dominant retinal disease. Clin Chem Lab Med 2000; 38:147-53.
19. Wong-Staal F, Poeschla EM, Looney DJ. A controlled, Phase 1 clinical trial to evaluate the safety and effects in HIV-1 infected humans of autologous lymphocytes transduced with a ribozyme that cleaves HIV-1 RNA. Hum Gene Ther 1998; 9:2407-25.
20. Long MB, Sullenger BA. Evaluating group I intron catalytic efficiency in mammalian cells. Mol Cell Biol 1999; 19:6479-87.
21. Collins CA, Guthrie C. The question remains: is the spliceosome a ribozyme? Nat Struct Biol 2000; 7:850-4.
22. Shastry BS. Hereditary degenerative retinopathies: optimism for somatic gene therapy. IUBMB Life 2000; 49:479-84.
23. Drenser KA, Timmers AM, Hauswirth WW, Lewin AS. Ribozyme-targeted destruction of RNA associated with autosomal-dominant retinitis pigmentosa. Invest Ophthalmol Vis Sci 1998; 39:681-9.
24. Lewin AS, Drenser KA, Hauswirth WW, Nishikawa S, Yasumura D, Flannery JG, LaVail MM. Ribozyme rescue of photoreceptor cells in a transgenic rat model of autosomal dominant retinitis pigmentosa [published erratum appears in Nat Med 1998 Sep; 4:1081]. Nat Med 1998; 4:967-71.
25. LaVail MM, Yasumura D, Matthes MT, Drenser KA, Flannery JG, Lewin AS, Hauswirth WW. Ribozyme rescue of photoreceptor cells in P23H transgenic rats: long-term survival and late-stage therapy. Proc Natl Acad Sci U S A 2000; 97:11488-93.
26. Flannery JG, Zolotukhin S, Vaquero MI, LaVail MM, Muzyczka N, Hauswirth WW. Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus. Proc Natl Acad Sci U S A 1997; 94:6916-21.
27. Altschuler M, Tritz R, Hampel A. A method for generating transcripts with defined 5′ and 3′ termini by autolytic processing. Gene 1992; 122:85-90.
28. Partono S, Lewin AS. The rate and specificity of a group I ribozyme are inversely affected by choice of monovalent salt. Nucleic Acids Res 1991; 19:605-9.
29. Birikh KR, Heaton PA, Eckstein F. The structure, function and application of the hammerhead ribozyme. Eur J Biochem 1997; 245:1-16.
30. Rossi JJ. Ribozyme therapy for HIV infection. Adv Drug Deliv Rev 2000; 44:71-8.
31. McConnell TS. Theoretical considerations in measuring reaction parameters. Methods Mol Biol 1997; 74:187-98.
32. Millington-Ward S, O'Neill B, Tuohy G, Al-Jandal N, Kiang AS, Kenna PF, Palfi A, Hayden P, Mansergh F, Kennan A, Humphries P, Farrar GJ. Strategems in vitro for gene therapies directed to dominant mutations. Hum Mol Genet 1997; 6:1415-26.
33. O'Neill B, Millington-Ward S, O'Reilly M, Tuohy G, Kiang AS, Kenna PF, Humphries P, Farrar GJ. Ribozyme-based therapeutic approaches for autosomal dominant retinitis pigmentosa. Invest Ophthalmol Vis Sci 2000; 41:2863-9.
34. Zern MA, Ozaki I, Duan L, Pomerantz R, Liu SL, Strayer DS. A novel SV40-based vector successfully transduces and expresses an alpha 1-antitrypsin ribozyme in a human hepatoma-derived cell line. Gene Ther 1999; 6:114-20.